Analytical Data
-
Gene name
PTGDR
- Application
-
Alternative Names
(PGD receptor)(PGD2 receptor)(Prostanoid DP receptor)
-
Species
Human
-
Source
E. coli
-
Tag
N- His & C- Myc
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q13258
-
Expression Region
217-262aa
-
Molecular Weight
12.8 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
PTGDR (Prostaglandin D2 Receptor 2) is a G-protein-coupled receptor that plays a significant role in various physiological processes, including the regulation of immune responses and the modulation of allergic reactions. Research into PTGDR has garnered attention due to its involvement in asthmatic conditions and other allergic diseases, where prostaglandin D2 serves as a pivotal mediator. Understanding the structure and function of PTGDR could provide insights into novel therapeutic strategies for treating respiratory disorders. Recent advancements in protein engineering, including recombinant protein expression, have enabled researchers to produce large quantities of PTGDR for structural and functional studies. This has opened avenues for elucidating the receptor's signaling pathways and interactions, paving the way for drug discovery efforts targeting PTGDR. Moreover, the exploration of PTGDR's role in other pathophysiological conditions, such as neurodegenerative diseases and cardiovascular disorders, emphasizes its potential as a multifaceted target in clinical research. Overall, the investigation of PTGDR and its recombinant protein forms is crucial for expanding our understanding of its biological significance and therapeutic potential.
